ארכיון
Lifetime Achievement Award to Prof. Yaakov Henkin | Update on Guidelines from the Last ESC 2025
מערכת האתר 11:01 סגור לתגובות על Lifetime Achievement Award to Prof. Yaakov Henkin | Update on Guidelines from the Last ESC 2025
A Unique case for use of Evkeeza
מערכת האתר 10:58 סגור לתגובות על A Unique case for use of Evkeeza
New Horizons for Treatments of Atherosclerosis (from LDL to Lp(a))
מערכת האתר 10:56 סגור לתגובות על New Horizons for Treatments of Atherosclerosis (from LDL to Lp(a))
Anti-Inflammatory Agents in Atherosclerosis: Performing or Underperforming?
מערכת האתר 10:54 סגור לתגובות על Anti-Inflammatory Agents in Atherosclerosis: Performing or Underperforming?
Debate: Case Presentation: Timing and Place of Bempedoic Acid or PCSK9i for ACS Patients with Partial Statin Intolerance
מערכת האתר 10:52 סגור לתגובות על Debate: Case Presentation: Timing and Place of Bempedoic Acid or PCSK9i for ACS Patients with Partial Statin Intolerance
Keynote Lecture: Anti-Atherogenic Effects of Eicosatetraenoic Acid (EPA). Underlying Mechanisms and Clinical Significance
מערכת האתר 10:48 סגור לתגובות על Keynote Lecture: Anti-Atherogenic Effects of Eicosatetraenoic Acid (EPA). Underlying Mechanisms and Clinical Significance
Session 3: Emerging Therapies
מערכת האתר 10:45 סגור לתגובות על Session 3: Emerging Therapies
Chairpersons: Dov Gavish & Kevin Jon Williams
The Effect of SGLT-2 Inhibitor (Empagliflozin) vs Resistance Training or Plant-Based Diet on Functional and Metabolic Aspects in Older Adults with Type 2 Diabetes
מערכת האתר 10:43 סגור לתגובות על The Effect of SGLT-2 Inhibitor (Empagliflozin) vs Resistance Training or Plant-Based Diet on Functional and Metabolic Aspects in Older Adults with Type 2 Diabetes
What did we Learn from the New GLP1 Agonist Trials?
מערכת האתר 10:40 סגור לתגובות על What did we Learn from the New GLP1 Agonist Trials?